Work

CML-413 Efficacy and Safety of Bosutinib Versus Imatinib in US Patients With Newly Diagnosed Chronic Myeloid Leukemia After 5-Years Follow-Up in the BFORE Trial

Year: 2022

Type: conference-abstract

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(22)01381-7

Authors: Vamsi Kota, Michael W. Deininger, Jason Mendler, Wei Shen, Erinn Goldmann, Jorge E. Cortes

Institutions: University of Rochester Medicine, University of Rochester, Pfizer (United States)

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4296963707

Cites:

Cited by: 2

Related to: 10